Azimilide dihydrochloride

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 3, 2005, Pages 387-391

  Carlson, Mark ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Implantable cardioverter defibrillator; Supraventricular tachycardia; Ventricular tachyarrhythmia; Ventricular tachycardia

Indexed keywords

ANTIARRHYTHMIC AGENT; AZIMILIDE; PLACEBO; POTASSIUM CHANNEL; SOTALOL;

ARTICLE; ASTHENIA; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART RATE; HEART REPOLARIZATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFECTION; META ANALYSIS; NEUTROPENIA; PHARMACOLOGICAL BLOCKING; QT INTERVAL; SYSTEMATIC REVIEW; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; HUMANS; IMIDAZOLIDINES; PIPERAZINES;

EID: 18844419540     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.3.387     Document Type: Article

References (10)

1. Salata JJ, Brooks RR. Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovasc. Drug Rev. 15, 137-156 (1997).
2. Pritchett ELC, Schulte MC, Schnell D et al. Azimilide Supraventricular Arrhythmia Program 3 (SVA3) investigators. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. J. Clin. Pharm. 42(4), 388-394 (2002).
3. Pritchett ELC, Marcello SR. Azimilide for atrial fibrillation: clinical trial results and implications. Cardiac. Electrophysiol. Rev. 7, 215-219 (2003).
4. Pritchett ELC, Page RL, Connolly SJ et al. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. Antiarrhythmic effects of azimilide in atrial fibrillation. Efficacy and dose response. J. Am. Coll. Cardiol. 36, 794-802 (2000).
5. Connolly SJ, Schnell DJ, Page RL et al. Dose-response relationships of azimilide in the management of symptomatic, recurrent atrial fibrillation. Am. J. Cardiol. 88(9), 974-979 (2001).
6. Page RL, Connolly SJ, Wilkinson WE et al., Azimilide Supraventricular Arrhythmia Program Investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose response. Am. Heart J. 143, 643-649 (2002).
7. Camm AJ, Pratt CM, Schwart PJ et al. Azimilide Post-Infarct Survival Evaluation (ALIVE): azimilide does not affect mortality in postmyocardial infarction patients. Circulation 104(25), 104 (2001).
8. Pratt CM, Singh SN, Al-Khalidi HR et al. Azimilide Post-Infarct Survival Evaluation (ALIVE) investigators. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 43, 1211-1216 (2004).
9. Singer I, Al-Khalidi H, Niazi I et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J. Am. Coll. Cardiol. 43, 39-43 (2004).
10. Dorian P, Borggrefe M, Al-Khalidi HR et al. on behalf of the Shock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 110, 3646-3654 (2004).